Enorama nicotine gum
- the pleasant way to quit smoking



Short time to market - approved in 8 EU markets

Enorama Pharmas is seeking partnership opportunities worldwide and has available market authorizations in several markets. We have approvals in 8 EU countries: Sweden, France, Spain, England, Germany, Poland, Greece & Denmark. Registration processes is ongoing in several other countries also outside of Europe. Our first launch is expected 2021 in the EU.

Ready for in-licensing

Enorama Pharma works B2B. We develop and manufacture the products and our customers market and distribute under their own brand. We have nicotine gum dossiers available for in-licensing and offers to supply the finished products ready for sale.

High growth rates

Nicotine Replacement Therapy (NRT) is in the top of all OTC-categories. Many factors drive the global NRT market, one of which is the increased awareness that smoking is a health hazards. This has led to an increasing number of people trying to quit smoking. In addition, governments and organizations are driving anti-smoking campaigns offering extended NRT-support. The increase in cigarette prices globally is another major driver of the market. 

to quit smoking:
  • Visually different
  • Soft chewing experience
  • Long-lasting flavor duration
  • Crunchy coating
  • Mint and fruit mint flavor
  • 2 and 4 mg strength
  • Patented
  • ChewMed® compressed technology
  • Bioequivalent to Nicorette®
  • 3 years shelf life
  • Zone 4B stability compliant
  • FDA and EMA manufacturing
  • Packaging options under development